Periodontal and implant-related diseases comprise a group of chronic conditions that are driven by challenge from bacteria in the supragingival plaque and biofilm in the subgingival niche of the periodontal environment. Chronic periodontitis is linked to a microbiota comprising a small group of around 15 of the 500 species or more that inhabit the oral cavity (96) . The progression of periodontal disease, as a consequence of either a lack of treatment (6, 71, 84, 87, 140, 144) or inadequate long-term management (11, 104) , results in ongoing attachment loss and bone resorption, which, with time, will compromise patient-related outcomes, such as tooth retention, esthetics and dental function. Dental implants are also susceptible to inflammatory diseases that are caused by the accumulation of biofilm. These conditions are categorized into those that are limited to the peri-implant soft tissues (peri-implant mucositis) and those that also affect the alveolar bone support (periimplantitis). Peri-implant mucositis is a reversible, inflammatory lesion which affects the marginal soft tissues that surround osseointegrated dental implants but does not involve resorption of the supporting bone. Conversely, peri-implantitis affects the supporting bone as well as the surrounding mucosa of a functioning implant (1, 85, 165) .
The conventional treatment of periodontal and peri-implant diseases involves cause-related therapy comprising a home-based oral-hygiene program, together with professional management (scaling, root or implant instrumentation), which may be undertaken nonsurgically or with surgical access to the affected sites. These anti-infective, professionally delivered treatments are, for the majority of patients, effective and lead into longer-term recall programs of supportive periodontal care. Such recall programs are an integral part of periodontal management (3) and are critical to prevent the progression of chronic diseases when they have been successfully stabilized following treatment. Even when teeth have been lost during the active stage of treatment, further tooth loss may be prevented if there is compliance with appropriate supportive periodontal care (7, 8, 24, 35, 101, 115) . Supportive periodontal care is therefore largely founded on the chronic nature of the disease, the ability or inability of the patient to maintain plaque levels that are consistent with stability, and the willingness and ability of the clinician to deliver the appropriate management (44) .
The aims of this paper are to outline the goals of supportive periodontal care programs (both for chronic periodontitis and for peri-implant diseases), to review the clinical-and cost-effectiveness of periodontal recall and to consider the additional treatment options available to the clinician when these goals have not been met. Within the context of this paper, the association of the recall programs is with supportive periodontal care, rather than with the prevention of periodontal disease in otherwise healthy patients (147) .
The goals of periodontal recall
The overarching goals of periodontal recall are to ensure that the periodontal or peri-implant tissues are maintained in a state of health, with achievement of an acceptable degree of disease stability, patient comfort and oral function. Of course, there are differences as to how this goal might be achieved for periodontally affected teeth compared with implants. Supportive periodontal care for patients with periodontal disease starts at the post-treatment stage, whereas, for implants, the supportive periodontal care commences after placement and at a point where no inflammatory change may yet be present. With this in mind, the aims of recall for both scenarios are broadly the same, namely to:
Minimize or halt the progression of inflammatory disease. Avert or postpone the loss of natural teeth (101) or implants, thus limiting the potential damaging biological (20) , psychological (106) and financial consequences.
Provide the clinician with an opportunity to identify and treat pathology at an early stage in order to improve long-term prognosis and treatment outcomes (30) .
To identify failing supportive periodontal care at the patient level it is crucial that the parameters of success are first considered. At present there are no universally agreed clinical outcomes, perhaps mainly because of the complex nature and progression of periodontal and peri-implant diseases, along with their multifactorial etiology. Furthermore, the criteria for success may well differ between the clinicians' and patients' perspectives.
The patients' concerns predominantly relate to tooth loss and ongoing functionality; however, the impact of supportive periodontal care, and indeed periodontal treatment, on these parameters are infrequently reported (66) . Such patient-centered outcomes may be either too complicated or long term to be measurable in real-time clinical trials and conversely the outcomes that concern clinicians may be difficult to relate to the contemporary concept of patient-centered care. Furthermore, the current lack of clear definition between periodontal or periimplant health makes the identification of success of supportive periodontal care in the long term quite challenging, and we still rely predominantly on clinical and radiographic outcomes to ascertain levels of success and failure (9, 18) .
Periodontal tissues
Whilst unequivocally it is clear that the presence of plaque following periodontal intervention predisposes to progression of clinical attachment loss (6, 7) , there is a lack of empirical evidence to suggest a specific, minimum threshold level of plaque that must be achieved, perhaps because quantification of plaque is not an accurate surrogate marker with which to predict disease progression (28) . Because of the complexity of the microflora associated with the etiology of periodontal disease, and the unequivocal role of the host response in determining risk and susceptibility, it is impossible, and probably unhelpful, to try to identify a universal minimum plaque level; the preferred option is to consider plaque control at the patient level whilst considering other risk factors, such as smoking. Nevertheless, typical plaque scores of 20-40% have been suggested as a goal for the majority of patients post-treatment and (by implication) throughout supportive periodontal care (82) .
Given the accepted influence of bacteria on periodontal and peri-implant diseases, there must be a strong focus on anti-infective measures. Although the biofilm rapidly reforms following debridement, repopulation of bacteria to baseline levels following periodontal treatment has been found to occur generally between 3 and 6 months after debridement (138) , which assists in determining recall regimens. It follows that an increased frequency of recall should favor stability of the periodontal tissues.
Bleeding on probing has also been proposed as one of the most reliable outcomes for determining appropriate intervals between supportive periodontal care recall appointments, given its strong, negative predictive value for periodontal disease. Bleeding on probing scores of between 10% and 20% have been proposed as the threshold below which a significant reduction in disease progression and subsequent attachment loss may be observed and stability and success may be more likely (74, 80) .
Periodontal sites with residual probing depths of < 5 mm, and those for which a reduction in probing depth of 2 mm is observed during supportive periodontal care following periodontal treatment, have been considered as clinically relevant minimal thresholds for identifying the site as being at nonrisk of future progression (92) and the patient classified as a positive responder to supportive periodontal care (114) . The specific criteria used to define progression does vary, however, with others suggesting, for example, that progression of disease (and presumably failing supportive periodontal care) is consistent with two or more teeth showing interproximal attachment loss of ≥ 3 mm between two time points (92, 150) or interproximal sites losing > 1.5 mm of attachment during longitudinal monitoring (86) . A critical search of the literature shows clear lack of consensus regarding the definition of success of supportive periodontal care (86, 92, 114, 127, 150) . Clinically, of course, at the site-specific level, varied responses are inevitable, depending, for example, on the initial depth of pocket and clinical attachment level and also whether interventions are of a surgical or a nonsurgical nature (63) . At sites where bleeding coexists with an increase in pocket depth of > 1 mm, then that site has a positive predictive value of 87% for subsequent development of bone and attachment loss (27) . Therefore, in summary, the goals of successful periodontal recall regimens for teeth may be achieved with (114, 150) :
Stabilization of plaque scores at 20-40%. Stabilization of bleeding scores at 10-25%. Probing-depth reductions and maintenance of probing depths between 1-2 mm (at 30% of sites).
Residual probing depths of < 5 mm. Gains in clinical attachment levels.
Peri-implant tissues
The goals of recall specific to peri-implant tissues are associated with the prevention of peri-mucositis and peri-implantitis, with the prevalence of these conditions being 43% and 22%, respectively (43) . A key aim of recall is to provide an opportunity for early identification of the onset of inflammation and therefore to halt the progression of peri-mucositis to peri-implantitis (37) . Whilst there is no consensus on the optimal measures to assess the long-term performance of implants other than simply survival or loss (99) , there are various clinical parameters that may be used to assess the status and stability of the peri-implant tissues at recall. The criteria for successful supportive periodontal care can be aligned to those outlined for periodontal disease by looking to maintain optimal plaque control around implant sites, recognizing that biofilm removal will address the key etiological factors in peri-implant disease (13) . Again, absence of bleeding on probing has a high negative predictive value and is a particularly strong indicator of stability of periimplant tissues (81, 89) . Indeed, as for natural teeth, bleeding around implant sites is predictive of active disease (128) .
The interpretation of probing depths can vary according to the depth of initial implant placement. The identification of a deep pocket alone, with no other accompanying signs, does not necessarily indicate the presence of pathology, and concerns regarding potential detrimental effects to the peri-implant mucosal seal have been shown to be unfounded, provided that a consistent probing force of no greater than 0.25 N is applied (46) .
Placement of the implant platform in a supracrestal position will probably result in minimal pocketing when compared with subcrestal placement, and as such it has been suggested that longitudinal comparison of probing depths from baseline may best indicate whether there is disease progression (91) . A minimum threshold of a 1 mm increase in probing depth has been suggested to classify a site with ongoing attachment loss (73) . Furthermore, any mobility of implants during supportive periodontal care suggests a failure of osseointegration and in such cases implant removal is indicated. Therefore, mobility of implants during supportive periodontal care is of little use in early identification of peri-implantitis (62); however, suppuration may be more helpful in determining supportive periodontal care management as it has been suggested as being indicative of bone loss of three or more implant threads (125) . The diagnosis of developing peri-implantitis can be confirmed through the identification of marginal crestal bone loss around the implant (130) . Baseline radiographs should be taken at placement and annually thereafter during supportive periodontal care (40) . There is a need to exercise caution regarding the appearance of bone loss adjacent to implants -coronal voids from over-aggressive countersinking, surgical trauma and even the inevitable consequence of loading may all predispose to marginal crestal bone loss (135) . Therefore, in summary, the goals of successful periodontal recall regimens for implants may be achieved with (108) 
Clinical effectiveness of supportive periodontal care
The literature is replete with studies of patients with chronic periodontitis who have been subjected to programs of supportive periodontal care. Our group has previously undertaken a systematic review to identify the more robust of these clinical trials, with the primary objective of identifying any differences between those managed intensively in specialist practice and those seen in the general dental services (54) . The inclusion criteria for the systematic review were studies:
Of patients with chronic periodontitis. Of supportive periodontal care following surgical and nonsurgical treatment in specialist and/or general care. With at least 12 months of follow up.
With clinical attachment as the primary outcome measure.
We have recently updated our search but found no additional studies that fulfil these criteria. The observations from the 14 original studies, however, provide robust evidence for the potential clinical effectiveness of supportive periodontal care (Table 1) and it is important for the clinician to be aware of the expectations of supportive periodontal care before considering whether, over a period of time, their management at patient or site levels can be considered as success or failure.
The findings of the systematic review (54) show clearly that patients on a program of care with frequent recall visits are likely to experience less clinical attachment loss and even, in some instances, attachment gain, when compared with those on programs of care with low-frequency and/or irregular recall visits (7, 38, 72, 75, 105, 110, 126, 161) . With regular supportive periodontal care provided every 3 or 4 months, attachment change is predominantly in the range of À0.85 (loss) to +0.25 (gain) and this is sustainable over periods of up to 12 years (7, 38, 72, 75, 105, 110, 117, 118, 126, 133, 161) . Attachment loss occurs across buccal, lingual and interproximal sites and irrespective of whether the initial periodontal treatment was surgical, nonsurgical or a combination of both (38, 75, 110, 117, 133, 161) . There is, however, limited evidence to suggest that greater loss occurs when supportive periodontal care follows surgical intervention (12) .
In response to the principal, focused question of the systematic review (54) , it was reported that frequent recall with a periodontist or dental hygienist in specialist care, or when periodontal care is provided as an intense program in a dental-school or hospital setting, generally leads to less attachment loss than when supportive periodontal care is delivered by a general dentist (32, 36, 92) . This difference tends to disappear when general dentists are provided with a clear prescription of the supportive periodontal care that they are expected to provide and even when there is a slight deterioration in plaque control over 12 months (112) .
Whilst these data are interesting and up to a point still provide the best available evidence for the expected outcomes of supportive periodontal care, it is important to note that data are reported as group means (either at the full-or part-mouth level). This does not allow identification of those specific unstable and deteriorating sites, which would be better markers of where supportive periodontal care is failing at the site level and thus allow the clinician to reevaluate and/or redeliver aspects of supportive periodontal care without having to resort to intuition. In contrast, in a 12-month study of 150 patients with moderate-to-advanced chronic periodontitis, supportive periodontal care delivered in private practice was more effective than that provided in a dental school, reducing sites with bleeding from 71% to 42%; reducing moderate (4-5 mm) and deep (≥ 6 mm) pockets from 22% and 7% to 3% and 0%, respectively; and reducing the number of sites with attachment loss of 4-5 mm and ≥ 6 mm from 31% and 24% to 18% and 11%, respectively (36) . These population data provide valuable indication of the expectations and limitations of supportive periodontal care at patient level and also reinforce the concept that, even with intensive supportive periodontal-care programs, it is crucial to identify those individual sites in which disease progression is likely. The data from this study (36) and others (92) suggest that for sites with probing depths of ≥ 6 mm, and with full-mouth bleeding prevalent at ≥ 30% sites, there is a clear risk for disease progression.
There is much less literature available to ascertain the effectiveness of supportive periodontal care for dental implants, and specifically the impact of supportive periodontal care in preventing the progression of an established mucositis to peri-implantitis. A key finding from the 2014 European Workshop of Periodontology concluded that lack of long-term supportive care in patients with mucositis was associated with an increased risk of peri-implantitis (73) . This confirmed earlier observations that the provision of regular supportive periodontal care over 5 years was able to restrict considerably the progression of mucositis to peri-implantitis (Table 1 ) (37).
Cost-effectiveness of supportive periodontal care
Having considered a number of treatment options for those patients who have sites that appear to be failing during supportive periodontal care, it is important to reflect on literature that may provide some insight into the cost-effectiveness of these management strategies. In doing so, we will then be able to provide patients not only with a prediction of the long-term clinical outcomes but also with a simple explanation for the estimate of the costs of achieving those outcomes and maintaining a periodontally stable dentition (49) .
To assess the economic aspects of having supportive periodontal care provided in general practice and in specialist practice, we previously constructed a model, using the data from the studies shown in Table 1 , to evaluate the cost-effectiveness of supportive periodontal care (54) . This model was constructed from the perspective of a single patient over a 30-year period being managed in the UK, and with loss of tooth years and clinical attachment as outcomes. Supportive periodontal care provided in specialist practice assumed 30-min appointments with a dental hygienist and recall visits every 3 months; supportive periodontal care provided in general practice assumed 20-min hygienist appointments with recall intervals every 6 months and was delivered both in private and publicly funded (government) care environments. The observations showed clearly, and perhaps not unexpectedly, that supportive periodontal care achieves greater periodontal stability and higher rates of tooth retention when delivered according to the more frequent recall visits in specialist practice than when delivered according to the timescale of the general dental services. This improved long-term outcome, however, comes at a higher financial cost to the patient, as shown by incremental cost-effective ratios, which represent the difference in cost divided by the difference in effectiveness between any intervention and the next best alternative (160). The incremental cost-effective ratio gives a measure of the cost per unit of effectiveness of implementing a more effective, but more costly, program (160) . For example, for supportive periodontal care in specialist practice, the incremental cost-effective ratio was €290 for one extra tooth year saved and €1500 for 1 mm less attachment loss over 30 years. Although this model was based on data from the UK, we later confirmed similar observations using data from across Europe, North America, Asia and Australasia (111) . In summary, supportive periodontal care delivered by a periodontist is more effective but comes at a higher cost than such care provided by a general dentist.
In terms of cost-effectiveness, the value of supportive periodontal care cannot be over-emphasized. Pretzl et al. (116) analyzed data from 98 patients who were in supportive periodontal care for 10 years and found, unsurprisingly, that the real costs for those who were regular attenders were higher than the costs for infrequent attenders. Crucially, however, the maintenance of a tooth through regular supportive periodontal care is considerably cheaper than extraction and replacement with dentures, implants or bridges, and so for patients with chronic periodontitis, supportive periodontal care is the most cost-effective option. Indeed, for those patients who opt not to enrol in maintenance care, the cost of lifelong supportive periodontal care will equate approximately to the cost of extraction and replacement of only three or four teeth (50) . Therefore, one approach suggested is to stress the financial benefit of supportive periodontal care to patients, with the view of using this as a potential 'lever' to improve compliance (116) . There has been much less consideration of the health economics of supportive periodontal care for implants. In one 'real-time' study set in a private periodontal practice in Norway, the mean cost of supportive care for an implant with peri-implantitis was €110 over the entire period of follow up, whereas the mean cost of supportive periodontal care for a tooth with periodontitis was €35. These figures relate to a mean cost/implant/year of €10.2 and a mean cost/tooth/year of €2.1 (48) . Hence, although the most cost-effective method for providing supportive implant care has yet to be established (132) , the costs of long-term supportive care has been estimated to be higher for implants than for natural teeth (48) .
What next?
It is now relevant to consider the strategies for managing a patient, for whom supportive periodontal care is failing, under two broad headings, namely: modification of predictive factors; and adjunctive treatments. In this context we define a predictive factor as one that is associated with a response or (in this instance) a lack of response to a particular therapy (supportive periodontal care) (29) . This implies that there will be a differential benefit from supportive periodontal care depending upon the status of the predictive factor. The modification of predictive factors is usually directed at the patient level, whereas the use of adjunctive treatments is directed at the site level, which depends on the sites at risk being identified. For the purpose of this review we will make the assumption that any site which does not respond to supportive periodontal care has already been assessed carefully for retained or reformed deposits and that any appropriate retreatment to remove these deposits has been undertaken.
Modification of predictive factors for supportive periodontal care
The principal patient-level factors that might affect the outcome of supportive periodontal care are the frequency of the recall visits, whether the patient is seen by a periodontist or their general dental practitioner, smoking habit, diabetes and compliance with the supportive periodontal care program.
Smoking and diabetes
The impact of smoking on limiting the benefit of periodontal treatment is well established (60, 77, 134, 149) with, in general terms, inferior clinical outcomes being observed in patients who continue to smoke (26, 113) , a finding reinforced by data from a recent meta-analysis of two longitudinal clinical trials (26) . Quitting smoking as part of periodontal management has a significant effect on resolving probing depths compared with nonquitting, and the effect is maintained over 9 months of supportive periodontal care (113) . Irrespective of smoking status, increased mean bleeding on probing values during supportive periodontal care has been shown to be associated with disease severity and periodontal instability in both smokers and nonsmokers, while smokers demonstrate lower mean bleeding on probing values concomitantly with an increased prevalence of residual probing pocket depths. Furthermore, bleeding on probing of ≤ 20% of sites in nonsmokers and quitters may also reflect disease stability, but more frequent supportive periodontal care recall visits are still recommended for smokers in this category because of their higher proportion of residual probing depths (113, 121) . Clinical data may also be apparently contradictory: for example, in a retrospective cohort study of patients seen over a time period of 11 years for supportive periodontal care, the prevalence of residual pockets of ≥ 5 mm increased in heavy smokers when compared with light smokers or nonsmokers, yet a shorter, prospective study over just 3 years demonstrated significantly shallower probing depths in nonsmokers compared with smokers, yet no significant difference in clinical attachment levels (51) . Perhaps of greater significance, however, was that neither probing depths nor attachment levels changed over 3 years when compared with the post-treatment baseline measurements, which reinforces the perception that whilst the clinical outcomes for smokers will probably be inferior to those for nonsmokers, the progression of disease during supportive periodontal care is unaffected by smoking status (51) . Nevertheless, in the absence of data that identify the clinical status of smokers who quit during supportive periodontal care, we must pursue the strategy of regular recall appointments for smokers and with advice to quit the habit based on the knowledge that quitting as part of periodontal treatment has a significant benefit on clinical outcomes (25, 26, 60, 77, 113, 134, 149) . The association of smoking and compliance with supportive periodontal care will be dealt with in a later section.
Another familiar and unequivocal risk factor for periodontal disease is poorly controlled diabetes and this appears to also be the case during supportive periodontal care. The evidence, however, is limited to a single study of 92 patients who attended regularly for supportive periodontal care over 5 years (34) . There was a higher odds ratio for both progression of attachment loss (odds ratio = 2.9) and tooth loss (odds ratio = 3.1) amongst those with poor glycemic control compared with those with good glycemic control or no diabetes (34) . An interaction between smoking and diabetes showed vastly elevated odds ratios for disease progression (odds ratio = 6.2) and tooth loss (odds ratio = 6.9) in this supportive periodontal care cohort, which again emphasizes the importance of glycemic control (and smoking cessation) in the long term, rather than the short term.
Frequency and duration of recall visits
As reported earlier in this review, those patients undergoing treatment in programs with frequent recall visits will be likely to demonstrate less clinical attachment loss when compared with patients receiving treatment in programs of care with irregular and less-frequent recall visits (7, 38, 72, 75, 105, 108, 110, 126, 127, 161) . When supportive periodontal care is provided every 3 or 4 months over periods of up to 12 years, attachment change in the range À0.85 to +0.25 is expected (7, 38, 72, 75, 105, 110, 117, 118, 126, 127, 133, 161) , which suggests that attachment loss of > 1 mm, over years rather than months, is indicative of failing supportive periodontal care and thus more frequent recall appointments should be considered.
Regarding duration of supportive periodontal care, for subjects on a program for < 10 years, only those probing depths of ≥ 7 mm were associated with a significantly higher risk for tooth loss in the longer term, whereas in those subjects on supportive periodontal care for ≥ 10 years, probing depths of 5 and 6 mm have been reported as being significantly associated with tooth loss. From a clinical point of view, this may indicate that there is a need for increased frequency of supportive periodontal care as patients age because recurrent disease becomes more prevalent (92) .
Provider of supportive periodontal care
It is unrealistic to expect specialist periodontists to provide supportive periodontal care on an indefinite basis and, at some point in the care-management process, the patient will be referred back to their general practitioner with a recommended strategy for long-term supportive periodontal care. This is an area that has not been researched extensively, although there is evidence to suggest that, at least in the short term, probing depths and bleeding on probing remain stable, irrespective of where the supportive periodontal care is provided (112) . However, the longer-term observations of Axelsson & Lindhe, in their classic paper, suggest that frequent recall and intensive supportive periodontal care with a periodontist, rather than a general dentist, will stabilize attachment levels and lead to less tooth loss over 6 years (7) . Furthermore, in a retrospective cohort study over 11 years, Matuliene et al. (92) reported that those patients who were treated and followed through supportive periodontal care in a university clinic environment received a higher frequency of recall appointments and had significantly fewer probing depths of 5 mm when compared with those patients discharged to their private dentists (17% vs. 30%). These data do not allow an unequivocal consensus to be made with any confidence regarding the best time during a supportive periodontal care program for the specialist to transfer responsibility of care to the general dentist and it is possibly best concluded that, until further evidence from longitudinal studies becomes available, each case should be considered on an individual basis. The issue of compliance will be covered in more detail in the following section, but of relevance here is the observation that the majority of 61 patients interviewed after periodontal treatment continued to attend their general dentist, rather than the specialist office, for supportive periodontal care (47) . The interview responses suggest that most patients are confident that their own dentist has the ability and skill set to maintain their periodontal health and the authors suggest that general dentists who diagnose disease and refer patients to a periodontist may have a particular interest in periodontology, may employ a dental hygienist and therefore may be in a better position and confident to deliver supportive periodontal care (47) .
Compliance with supportive care
Supportive periodontal care
Compliance with supportive periodontal care is clearly an essential prerequisite of long-term periodontal stability and maintenance of a functional dentition, yet the levels of compliance are often below 50% (42, 47, 79, 93, 102, 103, 107, 122, 145, 163) . For example, a study recruiting 427 patients treated for periodontal disease in a private periodontal practice identified that only about 50% of the cohort entered supportive periodontal care and, of these, 56% became nonattenders after 20 months and 33% became 'erratic' attenders after around 18 months, leaving only 10% attending regular recall after 5-6 years (41).
There is little doubt that compliance with supportive periodontal care is a complex issue and one that is of multifactorial etiology (153) . Some of these factors, such as the patient's age (120), which appears to have a positive association with compliance, are not easily modified; nevertheless, there are a number of factors that can be modified or addressed as part of supportive periodontal care. A significant, negative association between smoking and compliance with supportive periodontal care has been identified by Delatola et al. (41) and this was reinforced by Ramseier's group (120) , who demonstrated that 26% of 429 smokers never returned for supportive periodontal care after periodontal treatment. Furthermore, with respect to ultimate tooth loss, smokers with an erratic pattern of compliance with supportive periodontal care presented with higher rates of tooth loss (90%) compared with their nonsmoking counterparts (79%), whilst smokers who regularly complied with supportive periodontal care had only a moderately higher rate of tooth loss (45%) when compared with nonsmokers who regularly complied with supportive periodontal care (42%) (33) . These observations stress the need to address smoking as a risk factor as early as possible in the management plan, and the need for compliance with more regular recall appointments should be stressed to patients who continue to smoke.
Supportive implant care
The evidence for compliance with supportive implant care is not as extensive as for supportive periodontal care but nevertheless suggests a much higher rate of compliance for the former. For example, a 3-year study of 236 patients with 540 implants showed compliance rates of 95%, 92% and 86% at 1, 2 and 3 years, respectively (53) , whilst a longer study of 10 years' duration demonstrated a compliance rate (albeit with only one recall appointment/year) of 93%. Cardaropoli et al. (22) followed 74 patients through regular recall over 5 years for periodontal and/or implant support and reported a 77% compliance rate overall, but when patients had implants as well as periodontal treatment, the compliance increased to 88%. The authors suggest that the additional cost and effort required for implant placement may have increased motivation to attend regular recall appointments (22) .
Adjunctive treatments for supportive periodontal care
Clearly, repeated instrumentation at nonresponding sites during supportive periodontal care will compromise root substance and lead to an increase in tooth sensitivity. Alternative treatments (which have now been available for over 30 years) with no need for empirical instrumentation include the application of locally delivered antimicrobials. Many different drugs, alone or in combination have been incorporated into the products used for these treatments, which have been thoroughly investigated but mainly in clinical trials involving the treatment of chronic periodontitis rather than in supportive periodontal care. When locally delivered antimicrobials are used in various formulations (gels, strips, chips, powders, microspheres and fibers) at the treatment stage, the mean effect sizes for improvement in clinical attachment have been reported as 0.12 mm for metronidazole gel (57, 78, 83, 97, 109, 124, 143) , 0.16 mm for chlorhexidine (19, 58, 59, 69, 90, 142, 154) , 0.24 mm for tetracycline (52, 55, 70, 78, 83, 90, 100, 151, 154) and 0.46 mm for minocycline (56, 64, 78, 155, 159, 162) . It is a reasonable assumption, of course, to anticipate that the effects of using such applications for specific, failing sites during supportive periodontal care will be similar to those effects reported during the definitive treatment stage and although more robust data over extended periods of time are still needed, there is some evidence suggesting a potential role for the reapplication of local antimicrobials during supportive periodontal care. Repeated applications of microencapsulated minocycline plus instrumentation at 3 and 6 months during supportive periodontal care produced sustained and significantly better reductions in probing depth after 9 months than did instrumentation alone (162) . Similarly, greater improvements in probing depths and clinical attachment were seen after 15 months in patients with reapplications of a 2% minocycline ointment at 1 month following treatment and then at 3-month intervals for the following 12 months (156), although an earlier study of a similar design had failed to show any advantage of using this antimicrobial over the same time period (148) .
Slow-release doxycycline has also been used as an adjunct during supportive periodontal care (14, 39, 152) . A significant adjunctive effect in reducing probing depths (with bleeding) of > 5mm and attachment levels at 3 months, together with a benefit for probing depths of > 6 mm after 6 months, have been reported; however, these effects were not maintained at 12 months, which clearly demonstrates the relatively short-term benefit in reducing inflammation and suggests that their use during supportive periodontal care might have severe limitations unless reapplications are made (152) . A similar observation was also made when a single application of doxycycline was used as an adjunct to instrumentation at furcation sites, where improvement at 3 months could not be sustained after 6 or 12 months and the local delivery of doxycycline failed to reduce the need for additional instrumentation at nonresponding sites after the 12 months of the study. Furthermore, local application of doxycycline, repeated annually over 3 years, failed to show any benefit over instrumentation alone in patients undergoing periodontal maintenance therapy either from a clinical or a microbiological standpoint (14) . These data, both for minocycline and doxycycline, are promising but by no means unequivocally support the use of these antimicrobials in patients undergoing supportive periodontal care.
Cost-effectiveness of locally delivered antimicrobials
As part of any future evaluation, consideration must be given to the health economics of using local-delivery agents because several reapplications might be indicated over a period of time. The cost-effectiveness, cost benefit and patients' willing to pay for these treatments are paramount to their pragmatic inclusion in a program of care. Slots & Jorgensen (137, 139) were among the first to suggest that the costs of acquiring and administering drugs can be relevant in selecting which particular drug regimen to use as an intervention, particularly if the agents demonstrate equal efficacy and toxicity. Based on this suggestion, we reported an economic analysis using a model of supportive periodontal care with effectiveness data after 12 months (17, 65), a previously published profile of patients' characteristics (5), a direct source of treatment costs (in the UK) and a rationale for treatment regimens involving the use of adjunctive antimicrobials (Fig. 1) (61) . One comparison arm for the model was the provision of supportive periodontal care without adjunctive treatments (Fig. 1) . The real economic costs of the initial management and subsequent application of local antimicrobials during supportive periodontal care are shown in Table 2 and are based on UK economic data from 2009.
Calculations made to evaluate the cost-effectiveness of localized antimicrobials (minocycline gel, chlorhexidine chips or metronidazole gel) during treatment, and subsequently during supportive periodontal care, showed that the adjunctive use of metronidazole gel is less effective and more expensive than the adjunctive use of chlorhexidine chips (and therefore is unlikely to be cost-effective). The adjunctive use of minocycline is more expensive than that of chlorhexidine chips, but the additional cost, per millimeter gain in attachment level, is less. With this particular model, minocycline was cost-effective if a patient valued a millimeter in attachment gain on all affected teeth at a minimum cost of £1,800 in total. If a patient values this gain at between £1,500 and £1,800, then supportive periodontal care alone is cost-effective; for such a patient the additional gain from adjunctive minocycline did not justify the additional cost. So, in summary, and although this was only a model, the principal observation was that localized adjunctive antimicrobials can deliver nearly 1 mm of attachment gain throughout supportive periodontal care, but there is an additional cost. In general terms, the use of localized antimicrobials adds significantly more cost to the supportive periodontal care program. Their effects can be clinically significant but the extent to which they are used in supportive periodontal care will depend predominantly on the patients' willingness to pay.
A systematic review and meta-analysis regarding the efficacy of adjunctive local administration of antimicrobials in the treatment of perimucositis has deduced that within the limitations of the available studies they do not contribute any statistically significant clinical benefits (131) . Several studies have examined the effect of local delivery agents on periimplantitis, although in these studies the agents were principally administered at the time of initial treatment rather than during the supportive care phase.
The use of minocycline hydrochloride microspheres is promising (123, 129) and although other agents, such as tetracycline solution and doxycycline powder (2), polymeric tetracycline hydrogen chloride-containing fibers (95) and ornidazole (94) , have been investigated, their clinical efficacy and potential role within the supportive care phase remains uncertain (68, 157) . Further randomized clinical trials are required, whilst recognizing a potential effect of the implant surface texture in compromising the efficacy of any local antimicrobial treatment (21) . Furthermore, cultivated submucosal bacterial pathogens from sites of peri-implantitis have been shown to have a prevalence of resistance, of up to 46.7%, to the therapeutic concentrations of common individual antibiotics (119) . Given the current serious global concerns over the continued development of antibiotic-resistant bacterial strains (23), other adjuvant treatment strategies for supportive periodontal care and supportive implant care may need to be explored.
The problem of the nonresponding sites in patients undergoing supportive periodontal care has, more recently, led researchers to investigate the efficacy of novel mechanical and chemical methods, and their combinations, in periodontal maintenance populations. For example:
The relative effectiveness of a manual toothbrush with a fluoride dentifrice and a powered toothbrush in combination with a triclosan-containing dentifrice failed to demonstrate any clinical or microbiological superiority in 128 subjects after 1, Fig. 1 . Suggested treatment protocol for the use of adjunctive, locally delivered antimicrobials in the management of moderate-to-advanced chronic periodontitis. The model provides two options for the use of supportive periodontal care, with or without locally delivered preparations. It is assumed that following a period of supportive periodontal care there remain a number of pockets of > 6 mm. The locally delivered agents are then applied to these persistent pockets of ≥ 6 mm throughout a further period of supportive periodontal care over 12 months. It is also assumed that the local agents are used according to the manufacturers' instructions and, for example, unused gel or pastes may be reapplied at 2-weekly intervals for increased effectiveness and to avoid wastage.
2 and 3 years with the patients scheduled for 6-monthly recall appointments (15) . The introduction of a chemical plaque control intervention of 0.05% chlorhexidine and 0.05% cetylpyridium chloride was found to be effective in reducing plaque levels in a placebo-controlled trial that recruited patients who were noncompliant with plaque control (Turesky Index > 1) during supportive periodontal care. The study was only 3 months in duration, and so the conclusions are quite limited, but this observation suggests a possible option for patients who may be moved from an intense, supportive program to one of longerterm palliative management (45) . The use of subgingival air-polishing in recall patients has been investigated in both shortand medium-term studies (98, 164) . A 2-month study failed to demonstrate differences between interventions (air polishing or ultrasonic instrumentation) in clinical or microbiological outcomes after treatment, in pockets 5-8 mm deep that bled on probing (164) , and a 12-month trial of 50 patients undergoing recall failed to show superiority of air-polishing with an erythitol powder in combination with 0.3% chlorhexidine in comparison to ultrasonic debridement, although the air polishing was better accepted by the patients (98) . Five repeated applications of photodynamic laser were delivered over a 2-week interval to residual probing depths of ≥ 5 mm in a small cohort of 10 maintenance patients. The variability in outcomes at different follow-up time points, seen in trials of other interventions, is mirrored here because the laser intervention produced significant improvements in probing depths, attachment and bleeding at 6 months when compared with the control group, although only the improvement in bleeding was sustained after 12 months (88) . Photodynamic therapy has also been used in the early management of periimplantitis, with clinical outcomes being comparable to outcomes obtained following conventional instrumentation combined with locally delivered antimicrobials (10, 16) , however, the application of photodynamic therapy specifically to supportive implant care has yet to be determined. An Nd: YAG laser was used as an adjunct to instrumentation in probing depth sites of ≥ 5 mm in patients on supportive periodontal care for chronic periodontitis. The observations at 6 months showed no additional benefit of using the laser in this cohort (136) . Although some of the above investigations failed to show any additional benefit over that of the test treatment alone, no study showed that the test treatment was inferior to the control intervention. When the test treatment is used instead of instrumentation (i.e. rather than as an adjunct, for example, with the laser) then if such a treatment is shown to have greater patient acceptability and is economically more costeffective, then it may be the preferred option and especially so as it has to be reapplied on a regular basis.
A role for systemic antimicrobials?
First, it is important and pertinent to stress that when supportive periodontal care or supportive implant care appear to be failing and there are identifiable care management or behavioral factors that can be modified (e.g. frequency of recall, provider of care, smoking habit, standard of plaque control and compliance with the program), then every attempt should be made to address these factors before making any further decisions regarding the potential role for systemic antimicrobials or consigning the patient to a program of palliative periodontal management. The potential role of systemic antimicrobials in the management of chronic periodontitis continues to be a contentious issue amongst the periodontal community, and discussion and debate of the advantages and disadvantages of the role of systemic antimicrobials is outside the remit of this paper. Clinicians are directed to a recent pragmatic article that reviews the guidelines for the use of antibiotics in treating chronic periodontitis, the principles of dosing and selection and the properties of drugs that have been used for this purpose (4) . The authors identify continuing active disease as an indication for systemic drug therapy, but fail to define this term, either clinically or microbiologically. Nevertheless, their guidance is consistent with the recommendations made by van Winkelhoff & Winkel (158) in their excellent Commentary on the subject, in which they stress that systemic antimicrobials should be used with caution and only after determining the bacterial profile so that, for example, the regime of metronidazole and amoxicillin can be used for those patients with persistent infection with Porphyromonas gingivalis (76, 158) . Such reflection, of course, opens up the potential for use of systemic antimicrobials in those carefully selected, compliant patients on supportive periodontal care or supportive implant care, for whom plaque control is exemplary and, although mechanical treatment has been undertaken to the highest standard, there remain multiple bleeding and or suppurating pockets in excess of 5 mm (146) . The absolutely crucial point here is the need for bacterial profiling (to detect and quantify selected pathogens that are associated with disease progression) before antibiotic susceptibility surveillance testing, which, for patients on supportive periodontal care, may be undertaken in the longer term (every 2 years) to detect not only persistent pathogens but also changes in susceptibility profiles (van Winkelhoff Personal Communication). This service is available both at academic institutions (van Winkelhoff Personal Communication) and commercially (Micro-IDent â plus; Hain Diagnostics, Cookeville, TN, USA) with the emphasis being on the profiling of a range of pathogens rather than just of two or three known pathogens, which tended to be the case with the early chair-side tests.
Indeed, Actinobacillus actinomycetemcomitans (now Aggregatibacter actinomycetemcomitans), Bacteroides forsythus (now Tannerella forsythia) and P. gingivalis (31) were identified as causative factors for periodontitis based on the 1996 World Workshop in Periodontics consensus report. Current data from the Human Oral Microbiome Database, however, reflect the technological advances in molecular and gene-sequencing techniques over the last two decades, which have identified over 1,100 bacterial taxa in the oral cavity, of which 34% are still known only as uncultivated phylotypes (67) . This increase in knowledge of the oral microbiota has served to show increased complexity and the multispecies symbiotic relationship that exists within that microbial ecosystem, which is also far more complex than previously thought. Even accepting the added complications of potentially uncultivable pathogenic species, genetic variation and virulence factors, the current dogma still focuses on alteration of the bacterial ecosystempotentially with antimicrobials -to eradicate, or maintain, lower levels of periodontopathogens than needed for the progression of periodontal disease. Clinical improvement of periodontitis is associated with reductions in the levels, proportions or prevalence of associated pathogens (141) , and more recent evidence has shown that the significant reductions in 30 of 40 bacterial species (including T. forsythia, Treponema denticola and Eubacterium nodatum) following periodontal treatment can be maintained at 24 months (141). Thus, culture and sensitivity testing across a range of bacterial species before prescribing antimicrobials certainly has potential, in selected cases, of failing supportive periodontal care.
At the current time, there is a need for randomized clinical trials to assess the potential role of systemic antimicrobials in the supportive care of periodontitis and peri-implantitis (157) . The downside of systemic antibiotics for controlling the subgingival microflora is, of course, their contribution to the emergence of bacterial resistance and the potential for side effects (158) and, unlike the local delivery agents, their effectiveness depends on compliance of patients with dosing. A suggested treatment protocol using adjunctive systemic antimicrobials is shown in Fig 2. 
Cost-effectiveness of systemic antimicrobials
The cost-effectiveness of systemic antimicrobials as an adjunct to supportive periodontal care has previously been examined (61) . The analysis compared: (i) no intervention at a zero cost and leading to a loss of 0.1 mm clinical attachment level, (ii) supportive periodontal care without systemic antimicrobials (i.e. supportive periodontal care alone) costing £880 and leading to a gain of 0.5 mm in clinical attachment (i.e. an additional 0.6 mm), and, finally, (iii) supportive periodontal care + systemic metronidazole and amoxicillin costing £885 in total and giving a clinical attachment gain of 0.95 mm (or 1.05 mm in total vs. no intervention). Compared with the baseline of no intervention, supportive periodontal care + systemic metronidazole and amoxicillin gave an additional cost of £843 per extra millimeter of clinical attachment. The option of supportive periodontal care without antimicrobials was only slightly less costly but was significantly less effective and so not worth considering (and considered, in economic terms, to be extendedly dominated). The data that supported our previous analysis (65) did include antimicrobial sensitivity testing but the results of this testing were not used to determine which antimicrobials should be prescribed and therefore the effectiveness results reported are the same as if no antimicrobial sensitivity testing had been carried out. In addition, the costs calculated did not include any antimicrobial sensitivity testing.
For the purpose of this review, we have extended the previous cost-effectiveness analysis to include a fourth arm -that of supportive periodontal care + antimicrobials (prescribed on the basis of antimicrobial sensitivity testing) -in addition to the three arms of: no intervention; supportive periodontal care alone; and supportive periodontal care + systemic metronidazole and amoxicillin. No published data detailing the effectiveness of supportive periodontal care + systemic metronidazole and amoxicillin + antimicrobial sensitivity testing exist and Supportive periodontal care therefore a hypothetical approach was taken to determine the additional effectiveness that adding sensitivity testing would need to yield in order to change the conclusions of a cost-effectiveness analysis. For the costs, the previous analysis took the perspective of a patient in a direct payment system (i.e. all costs are passed onto the patient), and the cost of sensitivity testing was sought from two laboratories providing this service. The costs were $99 and €79.50, which were converted at a rate of $1 = £0.6955 and €1 = £0.7740 to give a mean cost of £65. It was assumed that the cost of different antimicrobials provided as a result of sensitivity would be negligibly different from the amoxicillin and metronidazole already costed into the supportive periodontal care + systemic metronidazole and amoxicillin arm. A further assumption was that even if sensitivity testing was undertaken, all patients would still receive systemic antimicrobials prescribed 'blind' (i.e. the results of sensitivity testing would influence which antimicrobials were prescribed, rather than whether any should be prescribed at all). Determining the hypothetical value at which decisions regarding the use of sensitivity testing would be influenced can be most easily explained by plotting clinical effectiveness vs. cost (Fig. 3) . As the cost is known (£885 + £65 = £950), the point of interest will lie on the interrupted vertical line. If the point lay directly on the intersection of the interrupted and solid lines, the effectiveness would be 1.027 mm. If the point moved along the vertical interrupted line so that it was above the solid line (i.e. the effectiveness was greater than 1.027 mm, or 0.077 mm greater than supportive periodontal care + systemic metronidazole and amoxicillin), then it would always be worth undertaking sensitivity testing as this approach would only be slightly more costly for significantly more effect than supportive periodontal care + systemic metronidazole and amoxicillin (supportive periodontal care + systemic metronidazole and amoxicillin is extendedly dominated in economic terms). If the point moves along the interrupted line to a point below the solid line, but is still greater than effectiveness of supportive periodontal care + systemic metronidazole and amoxicillin, then a judgement would need to be made as to whether the extra effectiveness was worth the extra cost. If the point moved further down the interrupted line to below the effectiveness level of supportive periodontal care + systemic metronidazole and amoxicillin, then supportive periodontal care + systemic metronidazole and amoxicillin would be more effective and less costly and so it would be inappropriate to prescribe supportive periodontal care + systemic metronidazole and amoxicillin + antimicrobial sensitivity testing (as supportive periodontal care + systemic metronidazole and amoxicillin + antimicrobial sensitivity testing would be dominated by supportive periodontal care + systemic metronidazole and amoxicillin).
Conclusion
When supportive periodontal care appears to be failing despite successful modification of predictive and behavioral factors, there are several factors that the clinician may consider. Increasing the frequency of recall visits and reverting to specialist management may help to stabilize the disease, whilst there is, as yet, sparse evidence for the benefit of additional treatment methods, such as laser therapy or air polishing, over conventional root instrumentation. Application of local antimicrobials is an option at specific failing sites, and systemic application of antimicrobials may be considered as a clinically and cost-effective regimen that is based, where possible, upon culture and sensitivity testing. preparing the manuscript; Professor A.J. #166, Cookeville, TN 38501) for their help in providing cost data for culture and sensitivity testing of subgingival microflora for use in our economic model. The authors received no funding for any research associated with this article and have no financial conflict of interests.
